Shamrock Pharmachemi is a part of Shamrock Group, which is involved in Contract Manufacturing, and export of APIs, Intermediates and Veterinary products for over 23 years. Over this period Shamrock has established itself as a recognizable brand promoting Indian APIs and Intermediates internationally.

The Shamrock Pharma Group is focused on providing customers high-quality APIs & Intermediates from its manufacturing & contract manufacturing facilities.

Shamrock customise the product suiting to customer and market requirements while meeting its quality standards and documentation to provide a long term supply chain for APIs.

The company has been recently acquired by SHAMROCK PHARMA GROUP and is now 100% owned by them. The new management brings in more accountability, commitment and better upgraded facilities to meet the high quality and regulatory requirements of global markets.

The company has a manufacturing record of more…

• Unimark Remedies Ltd., is a manufacturing company which provides affordable generic APIs for local and global markets.
• The company has a manufacturing record of more than 18 years and has been approved, inspected and audited by US FDA, EUGMP and other regulatory bodies on over 6 occasions.
• It has the state-of-the-art is designed to cater to all the regulated markets including USA. EU, CANADA and RoW.

• Largest integrated plant from chemical to vials. (Sterile)
• Leading developer of Carbapenems at USFDA Compliant facility.
• Dedicated facility for Orals Sterile / APIs / FDF – Carbapenems.
• Dedicated R&D for Carbapenems.
• USFDA / EUGMP / PMDA / KFDA / MHRA / TGA Compliant.
• 16 DMFs (Technical & Sterile) for Carbapenems

Complex Biological APIs, Starting Materials & Intermediates

Shamrock Biotech offers a focused portfolio of biological APIs, drug substances, starting materials and intermediates across anticoagulants, fertility, glycosaminoglycans, pulmonary surfactants and specialty biologicals.

Specialized Finished Dosage Forms for Critical Care, Hospital & Specialty Care

Shamrock Pharma Group offers a focused portfolio of critical-care, anti-infective, anticoagulant and specialty finished dosage forms, supported by specialized manufacturing, CMO/CDMO, technology transfer, dossier and global commercialization capabilities.

Shamrock Pharma Group offers a diverse portfolio of critical care finished dosage forms across key therapeutic categories, including anti-infectives, antifungals, anaesthetic agents, cardiovascular medicines, anticoagulants and other specialised therapies. The portfolio encompasses a range of injectable products, strengths and presentations, including vials, ampoules, lyophilised formulations and pre-filled syringes (PFS), catering to the diverse needs of pharmaceutical markets worldwide.